View as PDF
1L checkpoint inhibitor approvals have improved efficacy for many solid tumors and also widened the gap between 1L and 2L SoC
Despite some promising early results, Phase 3 trials investigating PD-(L)1 re-challenge have only succeeded in melanoma
Data from NSCLC trials suggests efficacy may be limited to patients with acquired, rather than primary, CPI resistance
Median Overall Survival (mOS) by Type of Resistance
In addition, control arms from these trials suggest that CPI may impact the efficacy of subsequent therapies, particularly in RCC
Are pending rechallenge Ph3 trials in NSCLC likely to produce different results?
Optimism is higher for SWOG's trial that selects for patients with prior PD-(L)1 benefit
Pending Pivotal PD-(L)1 Retreatment Trials – NSCLC
Since our last Pulse, 6 new oncology agents have been approved (including 4 bispecifics for heme indications)
2023 New Oncology Agents
Elia Farah, PhD
« Back to Pulse List
Oncology Pulse is our e-newsletter that looks at recent treads and promising directions in cancer treatments. Add your name to our maillist to receive future issues.
Bluestar BioAdvisors, LLC
521 Fifth Avenue, 25th Floor
New York, NY USA 10175
©2018–2023 Bluestar BioAdvisors, LLC. All rights reserved.